|
NuPathe Resubmits NDA for Migraine Patch
NuPathe has re-filed its NDA for its Zelrix migraine skin patch with fresh data, hoping to allay performance and packaging concerns that led to a complete response on the company’s first try.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives